Eukaryotic elongation factor 2 kinase as a drug target in cancer, and in cardiovascular and neurodegenerative diseases

Rui LIU, Christopher G PROUD*

South Australian Health & Medical Research Institute, North Terrace, Adelaide, SA5000, Australia

Eukaryotic elongation factor 2 kinase (eEF2K) is an unusual protein kinase that regulates the elongation stage of protein synthesis by phosphorylating and inhibiting its only known substrate, eEF2. Elongation is a highly energy-consuming process, and eEF2K activity is tightly regulated by several signaling pathways. Regulating translation elongation can modulate the cellular energy demand and may also control the expression of specific proteins. Growing evidence links eEF2K to a range of human diseases, including cardiovascular conditions (atherosclerosis, via macrophage survival) and pulmonary arterial hypertension, as well as solid tumors, where eEF2K appears to play contrasting roles depending on tumor type and stage. eEF2K is also involved in neurological disorders and may be a valuable target in treating depression and certain neurodegenerative diseases. Because eEF2K is not required for mammalian development or cell viability, inhibiting its function may not elicit serious side effects, while the fact that it is an atypical kinase and quite distinct from the vast majority of other mammalian kinases suggests the possibility to develop it into compounds that inhibit eEF2K without affecting other important protein kinases. Further research is needed to explore these possibilities and there is an urgent need to identify and characterize potent and specific small-molecule inhibitors of eEF2K. In this article we review the recent evidence concerning the role of eEF2K in human diseases as well as the progress in developing small-molecule inhibitors of this enzyme.

Keywords: mRNA translation; eEF2K; α-kinase; cardiovascular disease; hypertension; atherosclerosis; cancer; neurodegenerative disease; Alzheimer’s disease; depression

Acta Pharmacologica Sinica (2016) 37: 285–294; doi: 10.1038/aps.2015.123; published online 25 Jan 2016

Introduction

Protein synthesis is a crucial cellular process because almost all cell functions are performed by proteins and because the levels of proteins are determined in large part by the efficiency with which their mRNAs are translated into proteins[1]. However, protein synthesis and the production of ribosomes to support this process are expensive, consuming a large proportion of the cells’ energy and nutrients. Consequently, protein synthesis (mRNA translation) is subject to tight control, and numerous mechanisms have evolved to link nutrients, energy and other cues to the rates of protein production.

One such mechanism involves the phosphorylation of eukaryotic elongation factor eEF2, the protein that mediates the movement of ribosomes along mRNAs from one codon to the next during the elongation stage of translation[2]. Almost all of the energy and amino acids consumed by protein synthesis are used in elongation. When phosphorylated on Thr56 through its amino acid sequence, eEF2 cannot engage with ribosomes[3] and is essentially inactive in translation. eEF2 is phosphorylated by a highly specific protein kinase, eEF2 kinase (eEF2K). eEF2K is activated by Ca2+ ions via calmodulin (CaM), which immediately binds the N-terminal to its catalytic domain (Figure 1). The primary sequence of this domain does not resemble that of members of the main protein kinase superfamily, and indeed, eEF2K belongs to a small group of so-called α-kinases, which are represented by six genes in the human genome[4, 5]. Although a 3-dimensional structure for the catalytic domain of eEF2K is not yet available, such structures have been determined for two other α-kinases. This revealed a surprisingly high level of 3D similarity to members of the main kinase family, although there are also important differences[6-7]. The excellent review articles by Drennan and Ryazanov[8] and Middelbeek et al[9] provide more detailed information.
Recent discoveries have revealed roles for eEF2K in both cell physiology and disease. Given that eEF2K is the subject of a recent review, this article will focus on the most recent findings concerning eEF2K’s roles in cancer cell biology, as well as in cardiovascular disease and in neurological functions and neuropathology. In several but not all cases, eEF2K appears to promote disease progression by protecting cells against stresses. In neurodegenerative disease, it may exacerbate disease by inhibiting protein synthesis, which is required for cognitive functions. In all cases, it is suggested that inhibition of eEF2K may be therapeutically beneficial; e.g., by impairing cell survival in cancer and atherosclerosis and alleviating the inhibition of protein synthesis in Alzheimer’s disease (AD).

**Overview of the structure and control of eEF2K**

In addition to the N-terminal CaM-binding domain and catalytic domain, eEF2K also contains a C-terminal region hypothesized to contain α-helical repeats and a short, extreme C-terminal region, which is highly conserved and may interact with eEF2 (Figure 1). The center of the polypeptide is predicted to be unstructured and may act as a flexible linker between the two main folded regions of the protein (Figure 1).

eEF2K undergoes autophosphorylation, with a major site being Thr-348 (of the sequence of human eEF2K). This position corresponds to an autophosphorylation site in the related enzyme myosin heavy chain kinase (MHCK), which, when phosphorylated, docks into a binding pocket to allow the enzyme to adopt an active conformation. A similar mechanism appears to apply to eEF2K. This site can even be phosphorylated in E. coli, which lacks CaM, suggesting that the activity of eEF2K in autophosphorylation is not strictly Ca/CaM dependent. However, it is stimulated by Ca/CaM. The conformational change associated with the phosphorylation of Thr-348 enhances eEF2K activity by increasing its affinity for a (peptide) substrate and its intrinsic catalytic activity. The authors propose a two-stage ‘amplifier-like’ mechanism, where the first step involves the initial activation of eEF2K (off/on) and the second modulates its activity (through the stability of its active conformation, which is analogous to the volume control). Further work is clearly needed to define the structural changes that underpin this regulatory mechanism. The activity of eEF2K also modulates its proteasome-mediated degradation; however, it appears that the ability to assume an active conformation, rather than ongoing activity, is the key determinant here.

In addition to its activation by CaM, eEF2K is subject to a range of other inputs. In particular, it is inactivated by signaling downstream of the mammalian target of rapamycin complex 1 (mTORC1), which is stimulated by hormones, growth factors and nutrients; this can allow such anabolic stimuli to speed up the rate of elongation, and thus, protein synthesis. The first input from mTORC1 to be identified involves the 70 kDa ribosomal protein S6 kinase, p70S6K, which is activated by mTORC1 and phosphorylates eEF2K at Ser366 (human sequence numbering), inactivating it (Figure 1, 2). Since then, additional links between mTORC1 and eEF2K have been delineated, including direct phosphorylation of eEF2K by mTORC1 in an in vitro kinase assay, a nutrient-regulated protein kinase (Figure 1, 2). Ser78 in eEF2K is also phosphorylated in an mTORC1-dependent manner (Figure 1); this residue is adjacent to the CaM-binding motif, and its phosphorylation impairs CaM binding, and thus, the activation of eEF2K.

Because mTORC1 lies downstream of oncogenic signaling pathways, such as the phosphatidylinositol 3-kinase/Akt (protein kinase B) and Ras/Raf/MEK/ERK pathways, which are frequently dysregulated in cancers, it is likely that mTORC1 signaling is hyperactivated in a high proportion of tumors (estimated at 70%). The Ras/Raf/MEK/ERK pathway also makes direct inputs into the inactivation of eEF2K via direct phosphorylation of eEF2K by ERK (at Ser359) and via p90RSK, both of which are activated by ERK and phosphorylate eEF2K.

**Figure 1.** The structural layout of eEF2K. The drawing illustrates the major structural and functional features of eEF2K, the main known sites of phosphorylation, and the signaling pathways or kinases that regulate them. Solid lines show direct links and dashed lines show indirect links. The regions interacting with calmodulin (CaM) and eEF2 are also shown. The numbering of residues is based on human eEF2K. Green denotes active sites of phosphorylation, red denotes inhibitory sites, and grey indicates sites that are not known to affect activity. Sites in orange affect the phosphorylation of the sites at the extreme N-terminus, which can indirectly regulate activity.
The activation of AMPK[25, 26], but subsequent studies[13, 27, 28], a thiopyran-dicarbonitrile analog was described as[30, 31], This likely[20, 21], again likely by slow[32, 33], likely by reducing the rate[35, 36], This likely involves the inhibition of mTORC1, a negative regulator of eEF2K, while AMPK may also phosphorylate eEF2K directly, contributing to its activation.

α-Kinases do not possess a direct equivalent of the activation, or ‘T’-loop, which is found in members of the main protein kinase superfamily, and therefore, they do not require, or in the case of eEF2K, undergo phosphorylation within this feature of the catalytic domain (again, unlike regular protein kinases). α-Kinases do possess a different kind of loop, which approximately corresponds to the activation loop of other kinases and reflects the presence of glutamine and asparagine residues in this region, that is termed the N/D loop. One shared feature of those kinases and eEF2K is that this region plays a role in the binding and recognition of peptide or protein substrates. For example, point mutations within this region of eEF2K can alter its relative activity against eEF2, its physiological substrate, and a peptide substrate based on a myosin heavy chain (MH-I)[34].

**Inhibitors of eEF2K**  
As an atypical α-kinase, eEF2K is not inhibited by ‘classical’ protein kinase inhibitors, such as staurosporine[29]. This feature makes it more challenging to identify and further develop inhibitors for eEF2K, as they cannot simply be based on known kinase inhibitors, but does mean that such compounds are less likely to exert effects on other members of the main protein kinase family. Several reports have described compounds that can inhibit eEF2K activity (Table 1).

An early report of an eEF2K inhibitor concerned rottlerin[29], but this compound inhibits various other protein kinases at concentrations lower than those needed to inhibit eEF2K[30]. Subsequently, NH125, an imidazolium derivative, was reported to be an eEF2K inhibitor[31], but subsequent studies showed it actually increases eEF2 phosphorylation within cells, probably by acting as a non-specific protein-aggregating agent[32, 33]. A thiopyran-dicarbonitrile analog was described as an eEF2K inhibitor by Devkota et al[34]. A-484954 was uncovered by Abbott laboratories as a specific eEF2K inhibitor, but it is only weakly effective within cells[35]. A recent study created and tested a number of pyrido[2,3-b]pyrimidine-2,4-dione derivatives and found that two such compounds inhibited eEF2K activity with submicromolar IC₅₀s in vitro[35]. However,
Table 1. Summary of identified eEF2K inhibitors.

| Compound name                      | Structure*                                                                 | Experimental methods                                                                 | IC$_{50}$ (µmol/L) | Ref  |
|-----------------------------------|----------------------------------------------------------------------------|---------------------------------------------------------------------------------------|---------------------|------|
| Rottlerin                         | ![Structure](https://example.com/structure1.png)                           | Inhibitor of protein kinase Cδ. In vitro eEF2K kinase assay followed by autoradiography. Inhibits various other protein kinases more strongly than eEF2K. | 5.3                 | [28, 29] |
| 1-[6-[(3-Acetyl-2,4,6-trihydroxy-5- methylphenyl)methyl]-5,7-dihydroxy-2,2-dimethyl-2H-1-benzopyran-8-yl]-3-phenyl-2-propen-1-one, mallotoxin | |                                                                        |                     |      |
| TS-2                              | ![Structure](https://example.com/structure2.png)                           | 1,3-selenazine derivatives. In vitro eEF2K kinase assay followed by autoradiography. | 0.36                | [36] |
| TS-4                              | ![Structure](https://example.com/structure3.png)                           | In vitro eEF2K kinase assay followed by autoradiography. | 0.31                | [36] |
| NH125                             | ![Structure](https://example.com/structure4.png)                           | Imidazolium histidine kinase inhibitors. In vitro eEF2K kinase assay followed by either a filter-based assay or immunoblotting. | 0.06                | [31] |
| Compound 34                       | ![Structure](https://example.com/structure5.png)                           | Thieno[2,3-b]pyridine analogues. In vitro fluorometric, coupled-enzyme assay. | 0.17                | [37] |
| 2,6-diamino-4-(2-fluorophenyl)-4H- thiopyran-3,5-dicarbonitrile | ![Structure](https://example.com/structure6.png)                           | Method 1: Fluorescence-based assay that uses the phosphorylation of a Sox-based peptide (in vitro). | 60                  | [34] |
| 2-((3-cyano-4-(4-methoxyphenyl) pyridine-2-thio)-2-phenylacetic) acid | ![Structure](https://example.com/structure7.png)                           | Method 2: Luminescence-based assay that measures the amount of ATP remaining in the reaction (in vitro). | 77                  | [34] |
| A-484954                          | ![Structure](https://example.com/structure8.png)                           | Discovered by Abbott laboratories. In vitro kinase assay using myelin basic protein as substrate. | 0.28                | [32] |
| TX-1918                           | ![Structure](https://example.com/structure9.png)                           | 2-hydroxyarylidene-4-cyclopentene-1,3-dione analogues. In vitro eEF2K kinase assay followed by autoradiography. It also inhibits Src, PKA, PKC, and EGFR-K. | 0.44                | [38] |

* All the chemical structures in Table 1 were drawn with ChemSketch.
neither is more potent than A-484954, and each only caused partial inhibition of eEF2 phosphorylation, even at 75 µmol/L in MDA-MB-231 breast cancer cells. There is clearly an acute need to identify better eEF2K inhibitors as tool compounds to explore the roles of eEF2K in normal cell physiology and in disease. Such efforts have been hindered by the lack of a 3-dimensional structure for eEF2K but will be aided by the development of a homology model of eEF2K based on the known structures of two other members of the α-kinase family[39].

A positive role for eEF2K in cancer cell survival and tumor growth

As discussed in this section and the next, there is growing evidence of the roles of eEF2K in cancer and tumor progression, although the data at first appear conflicting (Figure 3). Several earlier studies have shown that eEF2K can protect cancer cells, especially glioma and breast cancer cells, against nutrient deprivation and some other insults[2] (Figure 3). Under such conditions, eEF2K is likely switched on by a combination of the inactivation of mTORC1 signaling and activation of AMPK. Possible mechanisms through which eEF2K may exert this effect have recently been discussed[40]. These studies, coupled with the fact that eEF2K is not essential, at least in mice under normal vivarium conditions, suggest that this enzyme may be an attractive target for cancer therapy.

Previous studies have indicated that eEF2K has a role in breast cancer cell survival[20, 41]. In the clinical setting, triple-negative breast cancers (TNBCs) are often resistant to therapy and readily metastasize. Liu et al[42] showed that compared to Pten or P53 single mutations, the combined deletion of Pten and P53 promotes the formation of claudin-low TNBC, which showed hyperactivated AKT signaling (although other data indicate that this pathway is not consistently induced in human Pten/P53-low TNBC). Such tumors also exhibited more mesenchymal features and poor clinical outcome, both of which are of interest because similar traits are observed in residual tumors after conventional therapy. The authors then employed a bias-free kinome-inhibitor screen to identify which pathways are important in these cells. Two inhibitors of eEF2K were effective, indicating that eEF2K is a promising target to tackle Pten/P53-deficient TNBC cells, especially those with high AKT activity. PI3-kinase, AKT and mTORC1 inhibitors were also identified in this screen, but they were not as effective as inhibitors of eEF2K (TX-1918 and NH125) or the c-Jun N-terminal kinase, JNK. Knocking down eEF2K suppressed cell growth two-fold under normal (nutrient-replete) conditions. By using chloroquine, an autophagy inhibitor, they found that eEF2K does not sustain tumor cell growth through autophagy. They reported eEF2K inhibitor NH125 suppressed xenograft growth of Pten/P53-deficient claudin-low TNBC in mice (BT549 cells introduced into NOD/SCID mice). The effect of TX-1918 was additive with doxorubicin treatment in mammary tumors in mice (human tumor TX-1918 cells).

Evidence that eEF2K impedes tumorigenesis

There are also data indicating that eEF2K has a negative role in cancer cell proliferation or tumor development (Figure 3). For example, the eEF2K inhibitor A-484954 has little inhibitory effect on the proliferation of lung and prostate cancer cells[32]. One recent study concerns colorectal cancer. The deletion of the Apc gene (adenomatous polyposis coli) is prevalent in the development of colorectal cancer. Following Apc deletion in

Figure 3. Links between eEF2K and the diseases discussed in this article. These include cardiovascular disease (CVD), certain cancers and Alzheimer’s disease. It should be noted that eEF2K also plays a positive role in cognition in some settings, eg, Conditioned Taste Aversion (see text). In general, the exact connections between eEF2K and the initiation or progression of these conditions remain to be elucidated.
mice, mTORC1 signaling is more active during crypt regeneration than it is in wild-type animals (as shown by immunohistochemical staining for the phosphorylated forms of the mTORC1 targets S6 and 4E-BP1\textsuperscript{[43]}). Both the stronger activation of mTORC1 and faster crypt regeneration after challenge (gamma-irradiation) in APC-deficient mice are dependent on Myc expression and can be reversed by rapamycin administration or raptor deletion, both of which impair mTORC1 signaling. Rapamycin administration can efficiently inhibit crypt regeneration and tumorigenesis driven by the loss of Apc. These striking data imply that components downstream of mTORC1 play an important role in these processes.

An Apc deficiency can increase the protein synthesis rate in the cultured intestinal crypt ([\textsuperscript{35}S]-labeled methionine/cysteine incorporation) and ribosome run-off rates but decrease the polysomal distribution, suggesting that elongation (but not initiation) is activated in the context of APC loss. Use of multiple knock-out and knock-in mouse models revealed that rapamycin inhibits the intestinal epithelium regeneration via mTORC1-regulated S6 kinase (S6K1)-eEF2K-eEF2 cascade. S6K1/2 knock out showed decreased intestinal regeneration, while the knock out of another effector of mTORC1 (4EBP1/2) had no effect, and the intestinal tissue was still sensitive to rapamycin. eEF2K deletion eliminated the inhibition by rapamycin of crypt generation. This indicates that eEF2K mediates a restriction on translation, which confers sensitivity to rapamycin, raising the question as to which mRNAs’ translation is critically regulated at the elongation stage. Further investigation showed that the elongation rate of cyclin D3 mRNA translation was higher in Apc-deficient cells than in wild-type cells and that cyclin D1 protein levels were reduced by rapamycin but not by eEF2K-knockouts. These studies indicate that blocking mTORC1 may be a useful way to treat early stage colorectal cancer, with its effects being mediated through eEF2K. These findings clearly appear to contrast with the data for tumor cells in vitro and with more limited in vivo (e.g., xenografts\textsuperscript{[44]}) findings, which indicate that eEF2K aids in the survival of tumors or tumor growth, especially under conditions of nutrient starvation.

Another study supporting the conclusion that eEF2K suppresses tumorigenesis was carried out in colon cancer cells. The authors of that study discovered that eEF2K suppresses autophagy, a process that can be utilized by cancer cells to survive under stress or nutrient-deprivation conditions\textsuperscript{[45]}. The authors found that the over-expression of eEF2K can significantly enhance the anti-tumor efficacy of oxaliplatin against colon cancer cells. These findings are consistent with the observation that eEF2K depletes the ATP levels in the cell, which would further activate AMPK. To test this hypothesis, they used the elongation inhibitor cycloheximide. This could completely block the phosphorylation of ULK1 and the LC3-II accumulation induced by eEF2K silencing, which could suggest that the removal of eEF2K activates the autophagy machinery by leading to excessive translation. However, cycloheximide has long been known to activate mTORC1 signaling\textsuperscript{[47, 48]}, which represses autophagy, and therefore it is hard to interpret these data. Overall, the data indicate that AMPK-ULK signaling is involved in the increased autophagy induced by eEF2K knock-down.

Further work is clearly needed to delineate the roles of eEF2K in tumor initiation or early development and in later-stage tumors, especially solid tumors. The utility of targeting eEF2K in cancer therapy may well depend on the tumor stage and type.

Wang et al.\textsuperscript{[49]} found that HLJDD (Huanglian Jiedu decoction), a traditional Chinese medicine that has been shown to have anti-cancer growth and anti-metastasis effects in clinical practice, can inhibit the proliferation of HepG2 hepatoma cells but is less potent in inhibiting the proliferation of MHCC97L cells (another type of hepatocellular carcinoma). This agent can also suppress angiogenesis (assessed using CD31 as an endothelial cell marker) and the growth of hepatocellular carcinoma xenografts (MHCC97L cells into nude mice). By using AHA (L-azidohomoalanine) labeling, they found that HLJDD inhibited protein synthesis in both HepG2 and MHCC97L cells at non-toxic doses. HLJDD had no effect on the phosphorylation of other translational components, such as eIF4A, eIF4E, and eIF4G. Nevertheless, by using compound C (an inhibitor of AMPK), the authors of that study found that HLJDD probably activates eEF2K via the AMPK/mTORC1 cascade. These data indicate that in hepatoma cells, the activation of eEF2K impairs tumor cell proliferation. The active components in HLJDD include geniposide, berberine, baicalin and palmatine, which have been shown to have anti-cancer effects. All of them induce the phosphorylation of eEF2 in an additive fashion. These components may also have other targets in addition to activating eEF2K.
eEF2K in cardiovascular disease

Recent studies have indicated that eEF2K has a role in cardiovascular disorders (Figure 3). Atherosclerosis is an important health challenge and a complex inflammatory disorder that involves the activation, proliferation and survival of macrophages. Oxidized low-density lipoprotein (oxLDL) blocks the apoptosis of macrophages and plays an important role in the pathogenesis of atherosclerosis. eEF2K is activated by oxLDL, likely through elevated Ca\(^{2+}\)-ion concentrations, and contributes to the survival of macrophages. In recent work, LDL-receptor knock-out mice were reconstituted (after irradiation) with bone marrow from mice harboring an inactivating mutation in the eEF2K gene and were then fed a high-fat diet to induce atherosclerosis. These mice displayed lower levels of atherosclerotic plaques than did LDLR-KO mice that received bone marrow with wild-type eEF2K. This is consistent with eEF2K playing a role in macrophage survival and thus in atherogenesis. Interestingly, M1-skewed (pro-inflammatory) macrophages from the eEF2K mutant mice secreted lower levels of a range of proteins involved in inflammation (eg, tumor necrosis factor-α, TNF-α) and leukocyte migration.

The pathogenesis of hypertension involves vascular remodeling through the proliferation and migration of vascular smooth muscle cells. Usui et al. tested the hypothesis that eEF2K controls the proliferation and migration of SMCs. The same group found that eEF2K increased in the mesenteric artery of spontaneously hypertensive rats (SHR). They revealed that eEF2K partially mediates hypertension in SHR via vascular inflammation. In cultured vascular endothelial and smooth muscle cells, eEF2K mediates TNF-α-induced vascular inflammatory responses via activation of ROS-dependent JNK and nuclear factor (NF)-κB signals. Platelet-derived growth factor (PDGF-BB)-induced SMC proliferation can be inhibited by eEF2K inhibitor A-484954 (as assessed by cell number and bromodeoxyuridine incorporation). The authors then used a Boyden chamber assay to show that PDGF-BB-induced SMC migration was significantly inhibited by A-484954. The FBS-induced outgrowth of SMCs is also inhibited by this compound. Interpretation of these data is compromised by the observation that A-484954 cannot inhibit the phosphorylation of eEF2 at T56 induced by PDGF-BB, but it did interfere with the phosphorylation of p38, ERK, and HSP27.

A further potential role for eEF2K has recently been reported in pulmonary arterial hypertension (PAH). This study found that eEF2K play roles in the remodeling of pulmonary arteries during the development of PAH. Administration of A-484954 can inhibit monocrotaline-induced PAH, which the authors suggest is mediated by eEF2K through the NADPH oxidase-1/Ros/matrix metalloproteinase-2 pathway, which plays an important role in PAH.

Neurological roles of eEF2K

eEF2K is expressed in neurons, and recent evidence suggests that it may play a role in processes such as learning and memory and in depression. Because the synthesis of new proteins is crucial for long-term memory, and Ca\(^{2+}\) ions are a key second messenger downstream of neurotransmitter receptors, there is considerable interest in the role of eEF2K in the processes that underlie synaptic plasticity, which likely provides the basis for memory. Park et al. showed that eEF2K plays an important role in the synthesis of Arc/Arg3.1, a protein involved in neurotransmitter receptor trafficking and in long-term depression, a process that reflects changes in synaptic strength. Gildish et al. used mice in which an inactivating mutation was introduced into the eEF2K gene. Their data showed that such animals displayed defective associative taste learning in a learning paradigm termed conditioned taste aversion. These animals also displayed abnormal brain activation, which was revealed by magnetic resonance imaging.

Given that the activation of eEF2K leads to the inhibition of protein synthesis, how could eEF2K regulate the increased synthesis of specific proteins? Early work showed that the inhibition of elongation can actually enhance the relative expression of proteins encoded by ‘weak’ mRNAs, which compete poorly for binding to ribosomes. By making elongation the limiting step, it is argued that slower rates of elongation allow such mRNAs to bind to ribosomes and thus become translated. Presumably, the impairment of elongation would have to be transient, initially allowing this process to occur and then being relieved to allow newly recruited mRNAs to be efficiently translated. A recent study in mouse cortical neurons showed that this is indeed the case in the response to bicuculline, a γ-aminobutyric acid receptor antagonist that increases Ca\(^{2+}\)-ion concentrations. This agent causes a rapid initial increase in eEF2 phosphorylation, which peaks within one min and then declines toward basal levels within 30–40 min. This decrease is driven by signaling through the classical MAP kinase (ERK) and mTORC1 pathways and is partially opposed by activation of AMPK, which can be switched on by Ca\(^{2+}\) ions. These signaling connections permit a transient rise in eEF2 phosphorylation, ie, a transient inhibition of elongation, which is consistent with the type of regulatory model described above.

Previous work suggested that ketamine, a fast-acting antidepressant, exerts its effects on the expression of brain-derived growth factor (BDNF), an important neuroregulatory protein, via the inhibition of eEF2K signaling, which normally negatively regulates BDNF expression. Ketamine enhances BDNF expression and exerts anti-depressive effects in wild-type mice but not in animals with eEF2K knock out. A study using eEF2K-deficient mice would be very important for determining whether eEF2K is a target for the development of new anti-depressant drugs. These and other aspects of the neurological roles of eEF2K are discussed in a recent review by Heise et al.

A very recent study indicates a quite different neurological role for AMPK and eEF2K in the setting of an AD model, in which amyloid β induces impairments of long-term potentiation (LTP) and depression (Figure 3). LTP is generally considered a form of synaptic plasticity associated with learning and memory formation. In this model, amyloid β causes the activation of AMPK, and this contributes to the observed impair-
ments in plasticity\textsuperscript{[60]. This raises the obvious question of which protein(s) downstream of AMPK mediate these effects. Ma et al\textsuperscript{[60]} showed that eEF2 phosphorylation is elevated in the hippocampus (a brain area crucial for learning) of AD model mice. Most importantly in the present context, the pharmacological inhibition of eEF2K improved the deficit in LTP in the AD mice but not in controls. This suggests that eEF2K may be a relevant target for ameliorating defects associated with AD, which represents a huge and rapidly growing global health challenge. However, further work using more specific eEF2K inhibitors than the one used here (NH\textsubscript{125}) and genetic models deficient in eEF2K activity is required to establish whether eEF2K is a useful target in this context. It is also important to bear in mind the positive roles, discussed above, of eEF2K in synaptic plasticity and learning.

Conclusion
As summarized above, eEF2K appears to play a role in a range of pathologies, including cardiovascular disease, cancers, neurodegeneration and, perhaps, depression (Figure 3). The precise mechanisms by which it does this remain to be established. eEF2K may do so through its effect on protein synthesis, a process that clearly has a fundamental impact both on the proteome and the cellular ‘economy’ (eg, energy and nutrient consumption). It is also possible that eEF2K has other substrates that are involved in some of these effects, although to date none have been identified. It is important to develop specific and potent small-molecule inhibitors of eEF2K for use in cell-based studies and especially in investigations using preclinical models of disease.

Acknowledgements
The work on the eEF2 kinase in Christopher G PROUD’s group is supported by the South Australian Health & Medical Research Institute.

References
1. Schwanhausser B, Busse D, Li N, Dittmar G, Schuchhardt J, Wolf J, et al. Global quantification of mammalian gene expression control. Nature 2011; 473: 337–42.
2. Kenney JW, Moore CE, Wang X, Proud CG. Eukaryotic elongation factor 2 kinase, an unusual enzyme with multiple roles. Adv Biol Regul 2014; 55: 15–27.
3. Carlberg U, Nilsson A, Nygard O. Functional properties of phosphorylated elongation factor 2. Eur J Biochem 1990; 191: 639–45.
4. Ryazanov AG, Pavur KS, Dorovkov MV. Alpha kinases: a new class of protein kinases with a novel catalytic domain. Curr Biol 1999; 9: R43–5.
5. Middelbeek J, Clark K, Venselaar H, Huynen MA, van Leeuwen FN. The alpha-kinase family: an exceptional branch on the protein kinase tree. Cell Mol Life Sci 2010; 67: 875–90.
6. Yamaguchi H, Matsushita M, Nairn AC, Kuriyan J. Crystal structure of the atypical protein kinase domain of a TRP channel with phosphotransferase activity. Mol Cell 2001; 7: 1047–57.
7. Ye Q, Crawley SW, Yang Y, Cote GP, Jia Z. Crystal structure of the alpha-kinase domain of Dictyostelium myosin heavy chain kinase A. Sci Signal 2010; 3: ra17.
8. Drennan D, Ryazanov AG. Alpha-kinases: analysis of the family and comparison with conventional protein kinases. Prog Biophys Mol Biol 2004; 85: 1–32.
9. Pyr Dit Ruys S, Wang X, Smith EM, Herinckx G, Hussain N, Rider MH, et al. Identification of autophosphorylation sites in eukaryotic elongation factor-2 kinase. Biochem J 2012; 442: 681–92.
10. Tavares CD, O’Brien JP, Abramczyk Y, Devkota AK, Shores KS, Ferguson SB, et al. Calcium/calmodulin stimulates the autophosphorylation of elongation factor 2 kinase on Thr-348 and Ser-500 to regulate its activity and calcium dependence. Biochemistry 2012; 51: 2232–45.
11. Crawley SW, Gharaei MS, Ye Q, Yang Y, Raveh B, London N, et al. Autophosphorylation activates Dictyostelium myosin II heavy chain kinase A by providing a ligand for an allosteric binding site in the alpha-kinase domain. J Biol Chem 2011; 286: 2607–16.
12. Wang X, Regufe da MS, Liu R, Moore CE, Xie J, Lanucara F, et al. Eukaryotic elongation factor 2 kinase activity is controlled by multiple inputs from oncogenic signaling. Mol Cell Biol 2014; 34: 4088–103.
13. Moore CE, Regufe da MS, Mikolajek H, Proud CG. A conserved loop in the catalytic domain of eukaryotic elongation factor 2 kinase plays a key role in its substrate specificity. Mol Cell Biol 2014; 34: 2294–307.
14. Tavares CD, Ferguson SB, Giles DH, Wang Q, Wellmann RM, O’Brien JP, et al. The molecular mechanism of eukaryotic elongation factor 2 kinase activation. J Biol Chem 2014; 289: 23901–16.
15. Kruiswijk F, Yuniati L, Magliozzi R, Low TY, Lim R, Bolder R, et al. Coupled activation and degradation of eEF2K regulates protein synthesis in response to genotoxic stress. Sci Signal 2012; 5: ra40.
16. Wang X, Xie J, da Mota SR, Moore CE, Proud CG. Regulated stability of eukaryotic elongation factor 2 kinase requires intrinsic but not ongoing activity. Biochem J 2015; 467: 321–31.
17. Wang X, Li W, Williams M, Terada N, Alessi DR, Proud CG. Regulation of elongation factor 2 kinase by p90\textsuperscript{Rsk1} and p70 S6 kinase. EMBO J 2001; 20: 4370–9.
18. Browne GJ, Proud CG. A novel mTOR-regulated phosphorylation site in elongation factor 2 kinase modulates the activity of the kinase and its binding to calmodulin. Mol Cell Biol 2004; 24: 2986–97.
19. Browne GJ, Proud CG. A novel mTOR-regulated phosphorylation site in elongation factor 2 kinase modulates the activity of the kinase and its binding to calmodulin. Mol Cell Biol 2004; 24: 2986–97.
20. Connolly E, Braunstein S, Formenti S, Schneider RJ. Hypoxia inhibits protein synthesis through a 4E-BP1 and elongation factor 2 kinase pathway controlled by mTOR and uncoupled in breast cancer cells. Mol Cell Biol 2006; 26: 3955–65.
21. Terai K, Hiramoto Y, Masaki M, Sugiyama S, Kuroda T, Hori M, et al. AMP-activated protein kinase protects cardiomyocytes against hypoxic injury through attenuation of endoplasmic reticulum stress. Mol Cell Biol 2005; 25: 9554–75.
22. Moore CE, Mikolajek H, Regufe da MS, Wang X, Kenney JW, Werner JM, et al. Elongation factor 2 kinase is regulated by proline hydroxylation and protects cells during hypoxia. Mol Cell Biol 2015; 35: 1788–804.
23. Dorovkov MV, Pavur KS, Petrov AN, Ryazanov AG. Regulation of elongation factor-2 kinase by pH. Biochemistry 2002; 41: 13444–50.
24. Hardie DG. AMP-activated protein kinase: maintaining energy homeostasis at the cellular and whole-body levels. Annu Rev Nutr 2014; 34: 31–55.
25. Iadevaia V, Liu R, Proud CG. mTORC1 signaling controls multiple steps in ribosome biogenesis. Semin Cell Dev Biol 2014; 36: 113–20.
26. Proud CG. Signalling to translation: how signal transduction pathways control the protein synthetic machinery. Biochem J 2007; 403: 217–34.
Horman S, Browne GJ, Krause U, Patel JV, Vertommen D, Bertrand L, et al. Activation of AMP-activated protein kinase leads to the phosphorylation of elongation factor 2 and an inhibition of protein synthesis. Curr Biol 2002; 12: 1419–23.

Browne GJ, Finn SG, Proud CG. Stimulation of the AMP-activated protein kinase leads to activation of eukaryotic elongation factor 2 kinase and to its phosphorylation at a novel site, serine 398. J Biol Chem 2004; 279: 12220–31.

Gschwendt M, Kittstein W, Marks F. Elongation factor-2 kinase: effective inhibition by the novel protein kinase inhibitor rortillin and relative insensitivity towards staurosporine. FEBS Lett 1994; 338: 85–8.

Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000; 351: 95–105.

Arora S, Yang JM, Kinzy TG, Utsumi R, Okamoto T, Kitayama T, et al. Identification and characterization of an inhibitor of eukaryotic elongation factor 2 kinase against human cancer cell lines. Cancer Res 2003; 63: 6894–9.

Chen Z, Gopalakrishnan SM, Bui MH, Soni NB, Warrior U, Johnson EF, et al. 1-Benzyl-3-cetyl-2-methylimidazolidone iodide (NH125) induces phosphorylation of eukaryotic elongation factor-2 (eEF2): a cautionary note on the anticancer mechanism of an eEF2 kinase inhibitor. J Biol Chem 2011; 286: 43951–8.

Devkota AK, Tavares CD, Warthaka M, Abramczyk O, Marshall KD, Kaoud TS, et al. Investigating the kinetic mechanism of inhibition of elongation factor 2 kinase by NH125: evidence of a common in vitro artifact. Biochemistry 2012; 51: 2100–12.

Devkota AK, Warthaka M, Edupuganti R, Tavares CD, Johnson WH, Ozpolat B, et al. High-throughput screens for eEF-2 kinase. J Biomol Screen 2013; 19: 445–52.

Edupuganti R, Wang Q, Tavares CD, Chijian CA, Bachman JL, Ren P, et al. Synthesis and biological evaluation of pyrido[2,3-d]pyrimidine-2,4-dione derivatives as eEF-2K inhibitors. Bioorg Med Chem 2014; 22: 4910–6.

Cho SI, Koketsu M, Ishihara H, Matsushita M, Nairn AC, Fukazawa H, et al. Novel compounds, '1,3-selenazine derivatives' as specific inhibitors of eukaryotic elongation factor-2 kinase. Biochim Biophys Acta 2000; 1475: 207–15.

Lockman JW, Reeder MD, Suzuki K, Ostanin K, Hoff R, Bhoite L, et al. Inhibition of eEF2K by thieno[2,3-b]pyridine analogues. Bioorg Med Chem Lett 2010; 20: 2283–6.

Hori H, Nagasawa H, Ishibashi M, Uto Y, Hirata A, Saiko K, et al. TX-1123: an anticancer 2-hydroxyarlylidene-4-cyclopentene-1,3-dione as a protein tyrosine kinase inhibitor having low mitochondrial toxicity. Bioorg Med Chem 2002; 10: 3257–65.

Wang Q, Edupuganti R, Tavares CD, Dalby KN, Ren P. Using docking and alchemical free energy approach to determine the binding mechanism of eEF2K inhibitors and prioritizing the compound synthesis. Front Mol Biosci 2015; 2: 9.

Leprivier G, Sorensen PH. How does oncogene transformation render tumor cells hypersensitive to nutrient deprivation? Bioessays 2014; 36: 1082–90.

Tekedireli I, Alpay SN, Tavares CD, Cobanoglu ZE, Kaoud TS, Sahin I, et al. Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to doxorubicin in an orthotopic model of breast cancer. PLoS One 2012; 7: e41171.

Liu JC, Voisin V, Wang S, Wang DY, Jones RA, Datti A, et al. Combined deletion of PTEN and p53 in mammary epithelium accelerates triple-negative breast cancer with dependency on eEF2K. EMBO Mol Med 2014; 6: 1542–60.

Faller WJ, Jackson TJ, Knight JR, Ridgway RA, Jamieson T, Karim SA, et al. mTORC1-mediated translational elongation limits intestinal tumour initiation and growth. Nature 2014; 517: 497–500.

Leprivier G, Remke M, Rotblat B, Dubac U, Mateo AR, Kool M, et al. The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation. Cell 2013; 153: 1064–79.

Xie CM, Liu XY, Sham KW, Lai JM, Cheng CH. Silencing of EEF2K (eukaryotic elongation factor-2 kinase) reveals AMPK-ULK1-dependent autophagy in colon cancer cells. Autophagy 2014; 10: 1495–508.

Py BF, Boyce M, Yuan J. A critical role of eEF-2K in mediating autophagy in response to multiple cellular stresses. Autophagy 2009; 5: 393–6.

Price DJ, Nemenoff RA, Avruch J. Purification of a hepatic S6 kinase from cycloheximide-treated rats. J Biol Chem 1989; 264: 13833.

Beugnet A, Tee AR, Taylor PM, Proud CG. Regulation of targets of mTOR (mammalian target of rapamycin) signalling by intracellular amino acid availability. Biochem J 2003; 372: 555–66.

Wang N, Feng Y, Tan HY, Cheung F, Hong M, Lao L, et al. Inhibition of eukaryotic elongation factor-2 confers to tumor suppression by a herbal formulation Huanglian-Jiedu decoction in human hepatocellular carcinoma. J Ethnopharmacol 2015; 164: 309–18.

Hundal RS, Salih BS, Schrader JW, Gomez-Munoz A, Duronio V, Steinbrecher UP. Oxidized low density lipoprotein inhibits macrophage apoptosis through activation of the PI 3-kinase/PKB pathway. J Lipid Res 2001; 42: 1483–91.

Chen JH, Riazy M, Smith EM, Proud CG, Steinbrecher UP, Duronio V. Oxidized LDL-mediated macrophage survival involves elongation factor-2 kinase. Arterioscler Thromb Vasc Biol 2009; 29: 92–8.

Zhang P, Riazy M, Gold M, Tsai SH, McNagny K, Proud C, et al. Investigating the kinetic mechanism of inhibition of eukaryotic elongation factor-2 kinase activity decreases atherosclerotic plaque formation. Can J Cardiol 2014; 30: 1684–8.

Usui T, Nijima R, Sakatsune T, Otani K, Kameshima S, Okada M, et al. Eukaryotic elongation factor 2 kinase controls proliferation and migration of vascular smooth muscle cells. Acta Physiol (Oxf) 2015; 213: 472–80.

Usui T, Okada M, Hara Y, Yamawaki H. Exploring calmodulin-related proteins, which mediate development of hypertension, in vascular tissues of spontaneous hypertensive rats. Biochem Biophys Res Commun 2011; 405: 47–51.

Usui T, Okada M, Hara Y, Yamawaki H. Eukaryotic elongation factor 2 kinase regulates the development of hypertension through oxidative stress-dependent vascular inflammation. Am J Physiol Heart Circ Physiol 2013; 305: H756–68.

Kameshima S, Kazama K, Okada M, Yamawaki H. Eukaryotic elongation factor 2 kinase mediates monocrotaline-induced pulmonary arterial hypertension via reactive oxygen species-dependent vascular remodeling. Am J Physiol Heart Circ Physiol 2015; 308: H1298–305.

Richter JD, Klann E. Making synaptic plasticity and memory last: mechanisms of translational regulation. Genes Develop 2009; 23: 1–11.

Costa-Mattioli M, Sossin WS, Klann E, Sonenberg N. Translational control of long-lasting synaptic plasticity and memory. Neuron 2009; 61: 10–26.

Park S, Park JM, Kim S, Kim JA, Shepherd JD, Smith-Hicks CL, et al. Elongation factor 2 and fragile X mental retardation protein control the dynamic translation of Arc/Arg3.1 essential for mGluR-LTD. Neuron 2015; 60: 293–307.

Geldish I, Manor D, David O, Sharma V, Williams D, Agarwala U, et al. Impaired associative taste learning and abnormal brain activation in kinase-defective eEF2K mice. Learn Mem 2012; 19: 116–25.
61 Walden WE, Thach RE. Translational control of gene expression in a normal fibroblast. Characterization of a subclass of mRNAs with unusual kinetic properties. Biochemistry 1986; 25: 2033–41.
62 Kenney JW, Sorokina O, Genheden M, Sorokin A, Armstrong JD, Proud CG. Dynamics of elongation factor 2 kinase regulation in cortical neurons in response to synaptic activity. J Neurosci 2015; 35: 3034–47.
63 Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng PF, et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 2011; 475: 91–5.
64 Nosyreva E, Kavalali ET. Activity-dependent augmentation of spontaneous neurotransmission during endoplasmic reticulum stress. J Neurosci 2010; 30: 7358–68.
65 Heise C, Gardoni F, Culotta L, Di LM, Verpelli C, Sala C. Elongation factor-2 phosphorylation in dendrites and the regulation of dendritic mRNA translation in neurons. Front Cell Neurosci 2014; 8: 35.
66 Ma T, Chen Y, Vingtdeux V, Zhao H, Viollet B, Marambaud P, et al. Inhibition of AMP-activated protein kinase signaling alleviates impairments in hippocampal synaptic plasticity induced by amyloid beta. J Neurosci 2014; 34: 12230–8.